BioMarin Pharmaceutical Price Target Cut to $112.00/Share From $115.00 by Morgan Stanley

BioMarin Pharmaceutical Price Target Cut to $112.00/Share From $115.00 by Morgan Stanley

Dow JonesApr 27 00:49

BioMarin Pharmaceutical Is Maintained at Hold by Canaccord Genuity

BioMarin Pharmaceutical Is Maintained at Hold by Canaccord Genuity

Dow JonesApr 26 20:58

Canadian Investment Banking Group: Maintaining the Biomarin Pharmaceutical (BMRN.US) rating, adjusted from holding to holding rating, and adjusted the target price from $91.00 to $89.00.

Canadian Investment Banking Group: Maintaining the Biomarin Pharmaceutical (BMRN.US) rating, adjusted from holding to holding rating, and adjusted the target price from $91.00 to $89.00.

Zhitong FinanceApr 26 20:50

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcript

Yahoo FinanceApr 26 20:49

Canaccord Genuity Maintains Hold on Biomarin Pharmaceutical, Lowers Price Target to $89

Canaccord Genuity analyst Whitney Ijem maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Hold and lowers the price target from $91 to $89.

BenzingaApr 26 20:48

Results: BioMarin Pharmaceutical Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shareholders are probably feeling a little disappointed, since its shares fell 8.8% to US$82.17 in the week after its latest quarterly results. It look

Simply Wall StApr 26 19:14